125 related articles for article (PubMed ID: 31231125)
1. E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients.
Lobo J; Petronilho S; Newell AH; Coach J; Harlow G; Cruz A; Lopes P; Antunes L; Bai I; Walker E; Henrique R
Mod Pathol; 2019 Nov; 32(11):1574-1586. PubMed ID: 31231125
[TBL] [Abstract][Full Text] [Related]
2. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
[TBL] [Abstract][Full Text] [Related]
3. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
4. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.
Turashvili G; McKinney SE; Goktepe O; Leung SC; Huntsman DG; Gelmon KA; Los G; Rejto PA; Aparicio SA
Mod Pathol; 2011 Jan; 24(1):64-81. PubMed ID: 20852590
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
Christgen M; Bartels S; van Luttikhuizen JL; Bublitz J; Rieger LU; Christgen H; Stark H; Sander B; Lehmann U; Steinemann D; Derksen PWB; Kreipe H
Mod Pathol; 2020 Dec; 33(12):2483-2498. PubMed ID: 32572153
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast.
Dabbs DJ; Kaplai M; Chivukula M; Kanbour A; Kanbour-Shakir A; Carter GJ
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):260-6. PubMed ID: 17721269
[TBL] [Abstract][Full Text] [Related]
7. Correlation between E-cadherin and p120 expression in invasive ductal breast cancer with a lobular component and MRI findings.
El Sharouni MA; Postma EL; van Diest PJ
Virchows Arch; 2017 Dec; 471(6):707-712. PubMed ID: 28779344
[TBL] [Abstract][Full Text] [Related]
8. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study.
Esposito NN; Chivukula M; Dabbs DJ
Mod Pathol; 2007 Jan; 20(1):130-8. PubMed ID: 17143261
[TBL] [Abstract][Full Text] [Related]
9. Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma.
Choi YJ; Pinto MM; Hao L; Riba AK
Mod Pathol; 2008 Oct; 21(10):1224-37. PubMed ID: 18587329
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions.
Sarrió D; Pérez-Mies B; Hardisson D; Moreno-Bueno G; Suárez A; Cano A; Martín-Pérez J; Gamallo C; Palacios J
Oncogene; 2004 Apr; 23(19):3272-83. PubMed ID: 15077190
[TBL] [Abstract][Full Text] [Related]
11. Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.
Gomes DS; Porto SS; Rocha RM; Gobbi H
Diagn Pathol; 2013 Jul; 8():114. PubMed ID: 23837653
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.
Ferreira C; Lobo J; Antunes L; Lopes P; Jerónimo C; Henrique R
Virchows Arch; 2018 Oct; 473(4):443-452. PubMed ID: 30006753
[TBL] [Abstract][Full Text] [Related]
13. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Heimann R; Lan F; McBride R; Hellman S
Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS.
Li X; Schwartz MR; Ro J; Hamilton CR; Ayala AG; Truong LD; Zhai QJ
Int J Clin Exp Pathol; 2014; 7(5):2551-7. PubMed ID: 24966968
[TBL] [Abstract][Full Text] [Related]
15. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
16. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
17. P-cadherin expression in breast carcinoma indicates poor survival.
Peralta Soler A; Knudsen KA; Salazar H; Han AC; Keshgegian AA
Cancer; 1999 Oct; 86(7):1263-72. PubMed ID: 10506713
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
[TBL] [Abstract][Full Text] [Related]
19. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
20. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
